New Laryngeal Cancer Treatment Could Aid Preservation
A new trial shows promising results for preserving the larynx in patients with advanced stage III-IVB throat cancer.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Do you believe immunotherapy-based cancer treatments generally offer more effective care than traditional chemotherapy regimens?
A phase II clinical trial shows that a pembrolizumab-based, cisplatin-free treatment regimen may offer a new path for organ preservation in patients with stage III-IVB laryngeal cancer. The approach achieved a two-year larynx preservation rate of 86% among study participants.
Why it matters
This approach explores whether pembrolizumab can support laryngeal preservation while avoiding the toxic side effects often associated with traditional cisplatin-based chemoradiotherapy. By reducing the need for laryngectomy, this regimen could potentially improve quality of life for patients facing advanced laryngeal cancer.
In a phase II clinical trial of 43 patients with stage III-IVB squamous cell carcinoma, the pembrolizumab-based regimen achieved a two-year laryngectomy-free survival rate of 65.1%. These preliminary findings also showed a two-year overall survival rate of 74.4%.
The players
SMART-KEY
A phase II clinical trial evaluating a pembrolizumab-based organ preservation strategy for laryngeal cancer patients.
The details
The treatment strategy replaces traditional cisplatin with induction therapy consisting of carboplatin, paclitaxel, and pembrolizumab given over three 21-day cycles. Patients then undergo concurrent intensity-modulated radiation therapy paired with pembrolizumab, followed by fourteen cycles of consolidation pembrolizumab. While this targeted approach aims to spare the larynx, 41.9% of participants experienced grade 3 or higher treatment-related adverse events, including 16.3% who experienced immune-mediated events.
Timeline
Patient enrollment for the SMART-KEY trial occurred from February 2022 to August 2023.
Trial results were presented at the ESMO Congress 2026 on October 26, 2026.
Health Landscape
Current treatment for advanced laryngeal cancer relies heavily on cisplatin-based chemoradiotherapy to control tumor growth while preserving the organ. This study marks a departure from that standard by testing an immunotherapy combination to manage the disease while reducing traditional chemotherapy toxicity.
Patients with advanced laryngeal cancer should discuss the potential risks and benefits of immunotherapy-based protocols with their oncology team. It is essential to understand that this study is preliminary, and individual treatment decisions must be made in consultation with a physician.
The takeaway
The study suggests that immunotherapy may support laryngeal preservation in advanced cases, though it carries a significant risk of grade 3 or higher adverse events. Patients should consult their specialists about emerging organ-preservation strategies and whether these clinical approaches are suitable for their specific diagnosis.
Further reading
For more information on current treatment standards and research developments, visit our Cancer section.
Source note: This article includes information reported by Oncodaily - Oncology News, Insights, Stories.
Live Poll
Do you believe immunotherapy-based cancer treatments generally offer more effective care than traditional chemotherapy regimens?
